We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

44 hedge funds and large institutions have $40.6M invested in Biolase, Inc. in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

13% more funds holding

Funds holding: 39 → 44 (+5)

2% more capital invested

Capital invested by funds: $40M → $40.6M (+$645K)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $75K

Holders
44
Holders Change
+5
Holders Change %
+12.82%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
3
Closed
2
Calls
–
Puts
$75K
Net Calls
-$75K
Net Calls Change
-$75K

Top Buyers

Rank Fund Capital Flow
1
OIM
Oracle Investment Management
Connecticut
+$5.79M
2
GTC
Ghost Tree Capital
New York
+$837K
3
State Street
State Street
Massachusetts
+$523K
4
PCM
Perkins Capital Management
Minnesota
+$488K
5
BFA
BlackRock Fund Advisors
California
+$140K

Top Sellers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
-$872K
2
NFA
Nationwide Fund Advisors
Ohio
-$74K
3
Northern Trust
Northern Trust
Illinois
-$69.8K
4
OC
Oppenheimer & Co
New York
-$57K
5
BIT
BlackRock Institutional Trust
California
-$34.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
26
AQR Capital Management
Connecticut
$102K – – –
ProShare Advisors
27
ProShare Advisors
Maryland
$84K +$105K +3 New
PPA
28
Parametric Portfolio Associates
Washington
$82K +$34.9K +1 +50%
Jane Street
29
Jane Street
New York
$74K +$69.8K +2 New
CS
30
Credit Suisse
Switzerland
$73K – – –
BA
31
BlackRock Advisors
Delaware
$67K – – –
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$67K – – –
GC
33
Guggenheim Capital
Illinois
$64K – – –
AIG
34
American International Group
New York
$56.5K – – –
Stifel Financial
35
Stifel Financial
Missouri
$52K +$69.8K +2 New
PC
36
Passport Capital
California
$50K +$69.8K +2 New
VKH
37
Virtu KCG Holdings
New York
$46K – – –
T. Rowe Price Associates
38
T. Rowe Price Associates
Maryland
$42K – – –
Deutsche Bank
39
Deutsche Bank
Germany
$34K – – –
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$32K – – –
PPSG
41
Princeton Portfolio Strategies Group
New Jersey
$31K – – –
Goldman Sachs
42
Goldman Sachs
New York
$25K +$34.9K +1 New
Citigroup
43
Citigroup
New York
$18K – – –
Bank of America
44
Bank of America
North Carolina
$14K – – –
WA
45
Waverly Advisors
Alabama
$6K – – –
MAM
46
Meeder Asset Management
Ohio
$5K – – –
Barclays
47
Barclays
United Kingdom
$3K – – –
TRCT
48
Tower Research Capital (TRC)
New York
$3K – – –
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$2.69K – – –
AllianceBernstein
50
AllianceBernstein
Tennessee
$2K – – –
1
2
3

BIOL Hedge Fund Activity: Q1 2014 in Review

44 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2014, worth a combined $40.6M — up 1.6% from $40M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BIOL positions and 2 closed out — a net gain of 5 holders — while 10 added to existing stakes and 3 trimmed.

The largest buyer was Oracle Investment Management, adding an estimated $5.79M. The largest seller was Eagle Asset Management, cutting an estimated $872K.

  • 44 institutional investors held Biolase, Inc. (BIOL) as of Q1 2014, up from 39 in Q4 2013.
  • Funds reported $40.6M of Biolase, Inc. stock for Q1 2014, up 1.6% quarter-over-quarter.
  • 7 funds opened new Biolase, Inc. positions in Q1 2014 and 2 closed out, a net change of +5 holders.
  • The largest Biolase, Inc. buyer in Q1 2014 was Oracle Investment Management, an estimated $5.79M added.
  • The largest Biolase, Inc. seller in Q1 2014 was Eagle Asset Management, an estimated $872K sold.

Based on aggregated 13F filings for Q1 2014.